Developer docs
API playgroundTry for free, no card

Search company profiles

Abion

Full company profile

uuid000bt62

Namestring
Abion
Legal namestring
ABION BIO
Websiteurl
abionbio.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Abion is a Seoul-headquartered, KOSDAQ-listed (ticker 203400) precision oncology biopharmaceutical company founded in 2007 by Professor Shin Young-ki of Seoul National University. The company is clinical-stage and pre-revenue, with a portfolio of approximately 12 pipeline candidates spanning small-molecule tyrosine kinase inhibitors (lead asset vabametkib / ABN401, a c-MET TKI in Phase 2 for NSCLC), antibody therapeutics (ABN501 targeting Claudin-3, the iRAC immune-engaging platform ABN202), and an interferon-beta dry-powder inhalation candidate (ABN101). The platform is supported by 81 registered patents and clinically validated research infrastructure including an AI-enhanced MET CTC liquid biopsy companion diagnostic trained on a 212-patient cohort. The company maintains a San Diego office to support US business development and clinical operations, alongside its Seoul R&D base.

The company makes money, to date, primarily through non-dilutive government grant funding (notably KDDF, supporting approximately KRW 98 billion for ABN401 development, and ADD research contracts) and equity financings including a KRW 85 billion rights offering and KRW 21 billion convertible bond in 2024. Forward revenue mechanics are expected to shift toward licensing upfronts, milestones, and royalties via out-licensing partnerships — including a signed Russia/CIS term sheet for vabametkib, ongoing discussions with a European Nasdaq-listed pharma for the same asset, and US-pharma discussions for ABN501 — supplemented by a planned US joint venture for the ABN202 iRAC platform representing approximately KRW 100 billion of investment.

Abion discontinued its CRO and biomed operations in 2023 to focus on proprietary new drug development. Capital structure is concentrated, with KPM Tech as the largest shareholder at 41.2% ownership. The lead asset vabametkib has been the subject of an FDA Orphan Drug Designation application (2024-02), a J&J drug supply agreement for combination evaluation with lazertinib (2024-06), and an IND submission for glioblastoma (2025-03). Pricing for any future commercial product is not publicly disclosed, consistent with the company's pre-commercialization stage.

Short descriptiontext

Abion is a Seoul-based, KOSDAQ-listed clinical-stage precision oncology biopharmaceutical company developing small-molecule and antibody therapeutics, including lead c-MET inhibitor vabametkib (ABN401) and Claudin-3 antibody ABN501, for global oncology indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, targeted cancer therapy, companion diagnostics, tyrosine kinase inhibitors, antibody drug development
Industry3 codes
PRIMARYHLAGAHAG
Impurity / Reference Standard Synthesis & Characterization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGACAK
Clinical Trial Pharmacy & IMP Management at Site
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Medical Laboratories8071
Product category
Clinical-Stage Oncology Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Transfer / Licensing-Out
TypeLicensing Royalties
Description

Abion aims to out-license its drug candidates (vabametkib, ABN501, ABN202) to global pharmaceutical companies. The company is in active LO discussions with multiple global pharma and biotech companies. Target upfront payments of KRW 60-100 billion plus milestone payments in the hundreds of billions of KRW. Russia/CIS technology transfer term sheet already signed. Discussions ongoing with a European Nasdaq-listed pharma company for broader regional deals.

abionbio.com
2Government Grants and Subsidies
TypeManaged Services
Description

Abion receives government funding for drug development through KDDF (Korea Drug Development Fund) and Ministry of Health and Welfare. KDDF selected vabametkib for KRW 7 billion support (2018 for preclinical), KRW 21 billion (2020 for Phase 1), and KRW 70 billion over 2 years (2023 for Phase 2 global clinical development). Also receives defense-related research grants from ADD for ABN101/ABN901 bio-defense projects.

abionbio.com
3Future Drug Product Sales
TypeOne Time License
Description

Upon regulatory approval, Abion plans to commercialize its drug candidates either independently or through distribution partnerships. Vabametkib targets the global c-MET inhibitor market projected to grow from $2.5B (2020) to $4.7B (2026). ABN101 targets the broad-spectrum antiviral prophylaxis market. The company listed on KOSDAQ (ticker 203400) for capital market access to fund development.

abionbio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Vabametkib (바바메킵)
Description

Brand name for ABN401, a c-MET tyrosine kinase inhibitor for non-small cell lung cancer

abionbio.com
+1 more record
Core offering1 text field

Abion is a clinical-stage biopharmaceutical company developing precision oncology and antiviral drug candidates. Its lead asset Vabametkib (ABN401) is a c-MET tyrosine kinase inhibitor for non-small cell lung cancer in global Phase 2 trials, supported by pipeline candidates including the Claudin-3 antibody ABN501, the iRAC antibody-cytokine fusion platform ABN202, and the second-generation interferon-beta dry powder inhaler ABN101. The company pairs its drug candidates with proprietary AI-enhanced liquid biopsy companion diagnostics and pursues out-licensing deals with global pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Vabametkib achieved 54% ORR overall and 75% ORR in treatment-naïve MET exon 14 NSCLC patients, compared to 48% and 68% for capmatinib (Novartis) respectively. Median PFS of 11.6 months as of May 9.
+4 more records
Product overview1 text field

Abion is a South Korean precision oncology therapeutics developer (KOSDAQ: 203400) with a portfolio of innovative drug candidates targeting Best-in-Class and First-in-Class treatments. The core pipeline includes: Vabametkib (ABN401), a Best-in-Class c-MET TKI for NSCLC currently in global Phase 2; ABN501, a First-in-Class Claudin 3 antibody for pan-carcinoma solid tumors in preclinical stage; and ABN101, a 2nd generation interferon-beta for broad-spectrum antiviral prophylaxis delivered via dry powder inhaler. Additional pipeline candidates include ABN202 (antibody-cytokine fusion platform), ABN601 (TLR5 agonist for acute radiation syndrome), ABN301 (HPV-targeting siRNA therapeutic), and ABN901 (biodefense vaccine). The company is developing companion diagnostics alongside its therapeutics and is pursuing strategic partnerships for global clinical development and technology transfer.

Product and service7 records
1Vabametkib (ABN401)
CategoryPrecision Oncology - Small Molecule Therapeutics
Description

Best-in-class c-MET tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) targeting MET exon 14 skipping mutations and MET amplification. Demonstrates superior safety profile (8.3% Grade 3+ TRAE vs 28-37.6% for competitors) and 54% ORR in Phase 2 trials. Being developed for NSCLC, glioblastoma, gastric cancer, and other c-MET-driven solid tumors.

2ABN501
CategoryPrecision Oncology - Antibody Therapeutics
Description

First-in-class Claudin-3 (CLDN3) targeting human monoclonal antibody for pan-carcinoma solid tumors including ovarian cancer and small cell lung cancer. High specificity and strong binding affinity with ADCC activity. Platform adaptable as ADC or CAR-T/CAR-NK cell therapy.

3ABN202
CategoryPrecision Oncology - Immuno-Oncology Platform
Description

Antibody-cytokine fusion protein platform (iRAC) combining interferon-beta mutein with tumor-targeting antibodies (Trop2, EGFR, VISTA/MSLN). Demonstrates superior anti-cancer efficacy compared to TROP2-targeting ADCs in preclinical models with ability to overcome ADC resistance.

4ABN101
CategoryAntiviral Therapeutics - Respiratory Infections
Description

Second-generation interferon-beta (biobetter) for broad-spectrum antiviral prophylaxis delivered via dry powder inhaler (DPI) formulation. Targets SARS-CoV-2, influenza, and RSV. Achieves >80% activity retention in dry powder form with 500x higher production yield than natural interferon-beta and 2.5 micrometer particle size for deep lung delivery.

5ABN601
CategoryBiodefense Therapeutics
Description

TLR5 agonist for acute radiation syndrome (ARS) treatment, developed for biodefense applications. Protects immune system when administered within 24 hours of radiation exposure, dramatically increasing survival rates.

6ABN301
CategoryPrecision Oncology - Nucleic Acid Therapeutics
Description

HPV-targeting siRNA-based nucleic acid therapeutic for head/neck cancer and cervical cancer, developed using proprietary drug delivery system (DDS) technology.

7ABN901
CategoryBiodefense Vaccines
Description

Biological defense vaccine candidate for military and biodefense applications, developed with support from Korea's Agency for Defense Development.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1European Nasdaq-Listed Pharmaceutical Company
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-03-31
Description

Abion is in active discussions with a European pharmaceutical company listed on Nasdaq for broader regional technology transfer of vabametkib covering Europe and North America. Originally the company sought full global rights but agreed to first close the Russia/CIS deal separately to accommodate Abion's current situation.

abionbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-28
Description

Abion plans to establish a joint venture company in the US in H1 2025 with a US biotech partner to accelerate ABN202 platform development. ~KRW 10 billion investment planned. Local US management to be appointed from the partner company to ensure development autonomy and speed. Abion to maintain controlling stake and transfer ABN202 technology to the JV.

3Russian Pharmaceutical Company (Russia/CIS)
Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2025-03-28
Description

Abion signed a term sheet with a Russian pharmaceutical company for technology transfer of vabametkib for Russia and 4 CIS (Commonwealth of Independent States) countries. Contract completion targeted within 2025. This is the first regional out-licensing deal for vabametkib.

abionbio.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-03-28
Description

Abion is in discussions with a US pharmaceutical company for technology transfer of ABN501 (Claudin-3 antibody). A term sheet is expected to be signed within the month, followed by main contract negotiations. ABN501 is being developed as a first-in-class pan-carcinoma antibody.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-25
Description

Abion signed a drug supply agreement with Janssen (J&J) for a combination clinical trial targeting EGFR-mutated NSCLC. Abion acts as the clinical trial sponsor while J&J provides lazertinib (Leclaza) at no cost. This collaboration investigates vabametkib (ABN401) in combination with J&J's EGFR inhibitor lazertinib to address resistance in NSCLC patients arising from c-MET alterations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-25
Description

Yuhan Corporation developed lazertinib (Leclaza), which is supplied through J&J for Abion's combination clinical trial. Lazertinib is an EGFR TKI that J&J obtained FDA approval for in combination with Rybrevant as first-line NSCLC treatment. Abion is combining vabametkib with lazertinib to address c-MET-mediated EGFR TKI resistance.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-05-12
Description

Abion partnered with Lapgenomics to develop COVID-19 vaccine using microneedle patch technology. The collaboration was supported by the International Health Technology Research Fund (Light Foundation) and achieved the first milestone of confirming antibody generation in animal models comparable to injection methods.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-05-12
Description

Abion signed a strategic partnership agreement with LabGenomics for companion diagnostic service development based on liquid biopsy. This partnership supports Abion's precision medicine approach by enabling biomarker-based patient selection for clinical trials.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-09-02
Description

Abion signed a CDMO (Contract Development and Manufacturing Organization) contract with Samsung Biologics for the development and manufacturing of ABN101, a second-generation interferon-beta for respiratory viral infections. The partnership covers preclinical sample production and ongoing clinical supply and API export production discussions.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Novartis markets capmatinib (Tabrecta), an FDA-approved c-MET TKI directly competing with Abion's lead asset vabametkib in MET exon 14 NSCLC. Same target, same indication, with established commercial infrastructure.

TypeDirect peer
Description

Merck KGaA markets tepotinib (Tepmetko), the other FDA-approved c-MET TKI for NSCLC. Direct competitor to vabametkib with similar label and established physician relationships.

TypeDirect peer
Description

Precision oncology small molecule developer targeting genetically defined cancers (acquired by BMS in 2024). Highly comparable business model: targeted oncology TKIs, companion diagnostic integration, and global out-licensing strategy.

TypeDirect peer
Description

Develops selective kinase inhibitors for genomically defined cancers and rare diseases. Comparable targeted oncology small molecule approach with companion diagnostic strategy and similar capital-light development model.

TypeRegional player
Description

Korean pharmaceutical company that developed lazertinib (Leclaza), the EGFR TKI supplied through J&J for Abion's combination trial. Strategic partner and regional peer with overlapping oncology focus in the Korean market.

TypeRegional player
Description

Major Korean pharmaceutical company with pipeline including targeted oncology and novel biologics. Comparable in terms of Korean biotech scale, KOSDAQ/KRX listing status, and pursuit of global licensing deals.

TypeEmerging player
Description

Korean biotech specializing in antibody engineering platforms for oncology and neurodegenerative diseases. Comparable in developing novel antibody platforms (Bispecific antibodies) and pursuing global pharma partnerships for out-licensing.

TypeEmerging player
Description

Swiss clinical-stage biotech developing DARPin-based therapeutics for oncology. Comparable platform-based approach to Abion's iRAC platform with similar engineering of alternative protein scaffolds for cancer therapy.

TypeEmerging player
Description

Swiss-Italian biotech specializing in antibody-cytokine fusion proteins for cancer treatment. Highly comparable to Abion's iRAC platform technology in fusing cytokines to tumor-targeting antibodies for solid tumor therapy.

TypeEmerging player
Description

Developer of antibody-drug conjugates (ADCs) including Elahere for ovarian cancer. Comparable to Abion's ABN501 (Claudin-3 antibody being adapted as ADC) and ABN202 (designed to overcome ADC resistance) in the ADC and antibody-cytotoxic space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abion

Clinical-Stage Oncology Therapeuticsabionbio.com

Abion is a Seoul-based, KOSDAQ-listed clinical-stage precision oncology biopharmaceutical company developing small-molecule and antibody therapeutics, including lead c-MET inhibitor vabametkib (ABN401) and Claudin-3 antibody ABN501, for global oncology indications.

What Abion does

Abion is a Seoul-headquartered, KOSDAQ-listed (ticker 203400) precision oncology biopharmaceutical company founded in 2007 by Professor Shin Young-ki of Seoul National University. The company is clinical-stage and pre-revenue, with a portfolio of approximately 12 pipeline candidates spanning small-molecule tyrosine kinase inhibitors (lead asset vabametkib / ABN401, a c-MET TKI in Phase 2 for NSCLC), antibody therapeutics (ABN501 targeting Claudin-3, the iRAC immune-engaging platform ABN202), and an interferon-beta dry-powder inhalation candidate (ABN101). The platform is supported by 81 registered patents and clinically validated research infrastructure including an AI-enhanced MET CTC liquid biopsy companion diagnostic trained on a 212-patient cohort. The company maintains a San Diego office to support US business development and clinical operations, alongside its Seoul R&D base.

The company makes money, to date, primarily through non-dilutive government grant funding (notably KDDF, supporting approximately KRW 98 billion for ABN401 development, and ADD research contracts) and equity financings including a KRW 85 billion rights offering and KRW 21 billion convertible bond in 2024. Forward revenue mechanics are expected to shift toward licensing upfronts, milestones, and royalties via out-licensing partnerships — including a signed Russia/CIS term sheet for vabametkib, ongoing discussions with a European Nasdaq-listed pharma for the same asset, and US-pharma discussions for ABN501 — supplemented by a planned US joint venture for the ABN202 iRAC platform representing approximately KRW 100 billion of investment.

Abion discontinued its CRO and biomed operations in 2023 to focus on proprietary new drug development. Capital structure is concentrated, with KPM Tech as the largest shareholder at 41.2% ownership. The lead asset vabametkib has been the subject of an FDA Orphan Drug Designation application (2024-02), a J&J drug supply agreement for combination evaluation with lazertinib (2024-06), and an IND submission for glioblastoma (2025-03). Pricing for any future commercial product is not publicly disclosed, consistent with the company's pre-commercialization stage.

Abion firmographics

Firmographics
Name
Abion
Legal name
ABION BIO
Website
https://abionbio.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Abion is a Seoul-based, KOSDAQ-listed clinical-stage precision oncology biopharmaceutical company developing small-molecule and antibody therapeutics, including lead c-MET inhibitor vabametkib (ABN401) and Claudin-3 antibody ABN501, for global oncology indications.
Ownership category
akta.pro rank

Abion industry classification

Industry
Product category
Clinical-Stage Oncology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAHAG
Impurity / Reference Standard Synthesis & Characterization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGACAK
Clinical Trial Pharmacy & IMP Management at Site
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)

Keywords

  • Precision oncology therapeutics
  • Targeted cancer therapy
  • Companion diagnostics
  • Tyrosine kinase inhibitors
  • Antibody drug development

Where Abion is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Abion business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Technology Transfer / Licensing-Out: Abion aims to out-license its drug candidates (vabametkib, ABN501, ABN202) to global pharmaceutical companies. The company is in active LO discussions with multiple global pharma and biotech companies. Target upfront payments of KRW 60-100 billion plus milestone payments in the hundreds of billions of KRW. Russia/CIS technology transfer term sheet already signed. Discussions ongoing with a European Nasdaq-listed pharma company for broader regional deals.
  2. Government Grants and Subsidies: Abion receives government funding for drug development through KDDF (Korea Drug Development Fund) and Ministry of Health and Welfare. KDDF selected vabametkib for KRW 7 billion support (2018 for preclinical), KRW 21 billion (2020 for Phase 1), and KRW 70 billion over 2 years (2023 for Phase 2 global clinical development). Also receives defense-related research grants from ADD for ABN101/ABN901 bio-defense projects.
  3. Future Drug Product Sales: Upon regulatory approval, Abion plans to commercialize its drug candidates either independently or through distribution partnerships. Vabametkib targets the global c-MET inhibitor market projected to grow from $2.5B (2020) to $4.7B (2026). ABN101 targets the broad-spectrum antiviral prophylaxis market. The company listed on KOSDAQ (ticker 203400) for capital market access to fund development.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Abion product offering

Product offering

Core offering

Abion is a clinical-stage biopharmaceutical company developing precision oncology and antiviral drug candidates. Its lead asset Vabametkib (ABN401) is a c-MET tyrosine kinase inhibitor for non-small cell lung cancer in global Phase 2 trials, supported by pipeline candidates including the Claudin-3 antibody ABN501, the iRAC antibody-cytokine fusion platform ABN202, and the second-generation interferon-beta dry powder inhaler ABN101. The company pairs its drug candidates with proprietary AI-enhanced liquid biopsy companion diagnostics and pursues out-licensing deals with global pharmaceutical partners.

Product overview

Abion is a South Korean precision oncology therapeutics developer (KOSDAQ: 203400) with a portfolio of innovative drug candidates targeting Best-in-Class and First-in-Class treatments. The core pipeline includes: Vabametkib (ABN401), a Best-in-Class c-MET TKI for NSCLC currently in global Phase 2; ABN501, a First-in-Class Claudin 3 antibody for pan-carcinoma solid tumors in preclinical stage; and ABN101, a 2nd generation interferon-beta for broad-spectrum antiviral prophylaxis delivered via dry powder inhaler. Additional pipeline candidates include ABN202 (antibody-cytokine fusion platform), ABN601 (TLR5 agonist for acute radiation syndrome), ABN301 (HPV-targeting siRNA therapeutic), and ABN901 (biodefense vaccine). The company is developing companion diagnostics alongside its therapeutics and is pursuing strategic partnerships for global clinical development and technology transfer.

Differentiator

Problem solved

Functional benefit

Brands

  • Vabametkib (바바메킵): Brand name for ABN401, a c-MET tyrosine kinase inhibitor for non-small cell lung cancer
  • iRAC Platform

Products and services

  • Vabametkib (ABN401) Best-in-class c-MET tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) targeting MET exon 14 skipping mutations and MET amplification. Demonstrates superior safety profile (8.3% Grade 3+ TRAE vs 28-37.6% for competitors) and 54% ORR in Phase 2 trials. Being developed for NSCLC, glioblastoma, gastric cancer, and other c-MET-driven solid tumors.
  • ABN501 First-in-class Claudin-3 (CLDN3) targeting human monoclonal antibody for pan-carcinoma solid tumors including ovarian cancer and small cell lung cancer. High specificity and strong binding affinity with ADCC activity. Platform adaptable as ADC or CAR-T/CAR-NK cell therapy.
  • ABN202 Antibody-cytokine fusion protein platform (iRAC) combining interferon-beta mutein with tumor-targeting antibodies (Trop2, EGFR, VISTA/MSLN). Demonstrates superior anti-cancer efficacy compared to TROP2-targeting ADCs in preclinical models with ability to overcome ADC resistance.
  • ABN101 Second-generation interferon-beta (biobetter) for broad-spectrum antiviral prophylaxis delivered via dry powder inhaler (DPI) formulation. Targets SARS-CoV-2, influenza, and RSV. Achieves >80% activity retention in dry powder form with 500x higher production yield than natural interferon-beta and 2.5 micrometer particle size for deep lung delivery.
  • ABN601 TLR5 agonist for acute radiation syndrome (ARS) treatment, developed for biodefense applications. Protects immune system when administered within 24 hours of radiation exposure, dramatically increasing survival rates.
  • ABN301 HPV-targeting siRNA-based nucleic acid therapeutic for head/neck cancer and cervical cancer, developed using proprietary drug delivery system (DDS) technology.
  • ABN901 Biological defense vaccine candidate for military and biodefense applications, developed with support from Korea's Agency for Defense Development.

Quantifiable outcome

  • Vabametkib achieved 54% ORR overall and 75% ORR in treatment-naïve MET exon 14 NSCLC patients, compared to 48% and 68% for capmatinib (Novartis) respectively. Median PFS of 11.6 months as of May 9.
  • +4 more outcomes

Companies that use Abion

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Abion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Abion partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered major and core.

  • European Nasdaq-Listed Pharmaceutical CompanymajorStrategic or Co-development Partner · 31 March 2025Abion is in active discussions with a European pharmaceutical company listed on Nasdaq for broader regional technology transfer of vabametkib covering Europe and North America. Originally the company sought full global rights but agreed to first close the Russia/CIS deal separately to accommodate Abion's current situation.
  • U.S. Biotech Companies (JV Partner)coreStrategic or Co-development Partner · 28 March 2025Abion plans to establish a joint venture company in the US in H1 2025 with a US biotech partner to accelerate ABN202 platform development. ~KRW 10 billion investment planned. Local US management to be appointed from the partner company to ensure development autonomy and speed. Abion to maintain controlling stake and transfer ABN202 technology to the JV.
  • Russian Pharmaceutical Company (Russia/CIS)majorGTM or Marketing Partner · 28 March 2025Abion signed a term sheet with a Russian pharmaceutical company for technology transfer of vabametkib for Russia and 4 CIS (Commonwealth of Independent States) countries. Contract completion targeted within 2025. This is the first regional out-licensing deal for vabametkib.
  • U.S. Pharmaceutical Company (ABN501)majorStrategic or Co-development Partner · 28 March 2025Abion is in discussions with a US pharmaceutical company for technology transfer of ABN501 (Claudin-3 antibody). A term sheet is expected to be signed within the month, followed by main contract negotiations. ABN501 is being developed as a first-in-class pan-carcinoma antibody.
  • Johnson & Johnson (Janssen Research and Development, LLC)coreStrategic or Co-development Partner · 25 June 2024Abion signed a drug supply agreement with Janssen (J&J) for a combination clinical trial targeting EGFR-mutated NSCLC. Abion acts as the clinical trial sponsor while J&J provides lazertinib (Leclaza) at no cost. This collaboration investigates vabametkib (ABN401) in combination with J&J's EGFR inhibitor lazertinib to address resistance in NSCLC patients arising from c-MET alterations.
  • Yuhan CorporationcoreStrategic or Co-development Partner · 25 June 2024Yuhan Corporation developed lazertinib (Leclaza), which is supplied through J&J for Abion's combination clinical trial. Lazertinib is an EGFR TKI that J&J obtained FDA approval for in combination with Rybrevant as first-line NSCLC treatment. Abion is combining vabametkib with lazertinib to address c-MET-mediated EGFR TKI resistance.
  • LapgenomicscoreTechnology or Integration · 12 May 2023Abion partnered with Lapgenomics to develop COVID-19 vaccine using microneedle patch technology. The collaboration was supported by the International Health Technology Research Fund (Light Foundation) and achieved the first milestone of confirming antibody generation in animal models comparable to injection methods.
  • LabGenomicscoreTechnology or Integration · 12 May 2023Abion signed a strategic partnership agreement with LabGenomics for companion diagnostic service development based on liquid biopsy. This partnership supports Abion's precision medicine approach by enabling biomarker-based patient selection for clinical trials.
  • Samsung BiologicscoreTechnology or Integration · 2 September 2019Abion signed a CDMO (Contract Development and Manufacturing Organization) contract with Samsung Biologics for the development and manufacturing of ABN101, a second-generation interferon-beta for respiratory viral infections. The partnership covers preclinical sample production and ongoing clinical supply and API export production discussions.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Abion competitors and assessment

Company assessment

Direct peers

  • Novartis: Novartis markets capmatinib (Tabrecta), an FDA-approved c-MET TKI directly competing with Abion's lead asset vabametkib in MET exon 14 NSCLC. Same target, same indication, with established commercial infrastructure.
  • Merck KGaA: Merck KGaA markets tepotinib (Tepmetko), the other FDA-approved c-MET TKI for NSCLC. Direct competitor to vabametkib with similar label and established physician relationships.
  • Mirati Therapeutics: Precision oncology small molecule developer targeting genetically defined cancers (acquired by BMS in 2024). Highly comparable business model: targeted oncology TKIs, companion diagnostic integration, and global out-licensing strategy.
  • Blueprint Medicines: Develops selective kinase inhibitors for genomically defined cancers and rare diseases. Comparable targeted oncology small molecule approach with companion diagnostic strategy and similar capital-light development model.

Regional players

  • Yuhan Corporation: Korean pharmaceutical company that developed lazertinib (Leclaza), the EGFR TKI supplied through J&J for Abion's combination trial. Strategic partner and regional peer with overlapping oncology focus in the Korean market.
  • Hanmi Pharmaceutical: Major Korean pharmaceutical company with pipeline including targeted oncology and novel biologics. Comparable in terms of Korean biotech scale, KOSDAQ/KRX listing status, and pursuit of global licensing deals.

Emerging players

  • ABL Bio: Korean biotech specializing in antibody engineering platforms for oncology and neurodegenerative diseases. Comparable in developing novel antibody platforms (Bispecific antibodies) and pursuing global pharma partnerships for out-licensing.
  • Molecular Partners: Swiss clinical-stage biotech developing DARPin-based therapeutics for oncology. Comparable platform-based approach to Abion's iRAC platform with similar engineering of alternative protein scaffolds for cancer therapy.
  • Philogen: Swiss-Italian biotech specializing in antibody-cytokine fusion proteins for cancer treatment. Highly comparable to Abion's iRAC platform technology in fusing cytokines to tumor-targeting antibodies for solid tumor therapy.
  • ImmunoGen: Developer of antibody-drug conjugates (ADCs) including Elahere for ovarian cancer. Comparable to Abion's ABN501 (Claudin-3 antibody being adapted as ADC) and ABN202 (designed to overcome ADC resistance) in the ADC and antibody-cytotoxic space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Abion social profiles

Digital presence

Abion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abion leadership team

Management profile

Number of profiles

Profiles5 records

Abion funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abion

What does Abion do?

Abion is a clinical-stage biopharmaceutical company developing precision oncology and antiviral drug candidates. Its lead asset Vabametkib (ABN401) is a c-MET tyrosine kinase inhibitor for non-small cell lung cancer in global Phase 2 trials, supported by pipeline candidates including the Claudin-3 antibody ABN501, the iRAC antibody-cytokine fusion platform ABN202, and the second-generation interferon-beta dry powder inhaler ABN101. The company pairs its drug candidates with proprietary AI-enhanced liquid biopsy companion diagnostics and pursues out-licensing deals with global pharmaceutical partners.

Is Abion a public or private company?

Abion is a public company. It is classified as public and is currently operating.

When was Abion founded?

Abion was founded in 2007. It employs 11 to 50 people.

Where is Abion based?

Abion is headquartered in Seoul, South Korea, in the Asia region.

How does Abion make money?

Three revenue lines are on record. Technology Transfer / Licensing-Out is the primary driver. The others are government Grants and Subsidies and future Drug Product Sales.

Who are Abion's main competitors?

Direct peers on record are Novartis, Merck KGaA, Mirati Therapeutics and Blueprint Medicines. Regional players are Yuhan Corporation and Hanmi Pharmaceutical. Emerging players are ABL Bio, Molecular Partners, Philogen and ImmunoGen.

Does Abion have an API?

No public API is recorded for Abion.

What industry is Abion in?

Abion's product category is Clinical-Stage Oncology Therapeutics. Its primary akta.pro industry code is HLAGAHAG, Impurity / Reference Standard Synthesis & Characterization, with a secondary code of HLAGACAK, Clinical Trial Pharmacy & IMP Management at Site. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comABION’s ABN202 shows promise against ADC-resistant tumors in study By Investing.comABION announced that its immuno-oncology candidate ABN202 demonstrated anti-cancer activity in preclinical studies against TROP2-targeting ADC-resistant tumors, with findings to be presented at the AACR conference in San Diego in April. The drug candidate, based on the iRAC platform, showed it could induce CD8-positive T cell-mediated immune responses and may be applicable to various solid tumor targets beyond TROP2. The company plans to submit an Investigational New Drug application in the first half of next year and is exploring strategic partnership opportunities for ABN202.BioSpaceABION Presents Preclinical Data at AACR Showing IFN-β Antibody Fusion ABN202 Outperforms TROP2-Targeting ADCsABION presented preclinical data at AACR 2026 showing its immuno-oncology candidate ABN202, based on the proprietary iRAC platform, demonstrated superior anti-cancer mechanism compared with approved TROP2-targeting antibody-drug conjugates (ADCs). The study found ABN202 overcame resistance to existing ADC therapies and induced sustained CD8-positive T cell-mediated immune responses, suggesting potential for durable anti-tumor immunity in solid tumor patients who failed prior ADC-based treatments. The company is accelerating toward IND submission in H1 next year and actively exploring strategic partnership opportunities for ABN202.PharmiWeb.comABION Presents Preclinical Data at AACR Showing IFN-β Antibody Fusion ABN202 Outperforms TROP2-Targeting ADCsABION announced at AACR 2026 that its next-generation immuno-oncology candidate ABN202 demonstrated superior anti-cancer mechanisms compared to TROP2-targeting ADCs in preclinical studies, including the ability to overcome ADC resistance and induce sustained CD8-positive T cell-mediated immune responses. The company plans to submit an Investigational New Drug application in the first half of next year and is exploring strategic partnership opportunities for ABN202. The drug candidate is based on ABION's proprietary iRAC platform, which can be applied to a broad range of solid tumor targets beyond TROP2.MorningstarABION Presents Preclinical Data at AACR Showing IFN-β Antibody Fusion ABN202 Outperforms TROP2-Targeting ADCsABION, a South Korean precision oncology therapeutics developer listed on KOSDAQ, announced that its next-generation immuno-oncology candidate ABN202 demonstrated superior anti-cancer activity compared to currently approved TROP2-targeting antibody-drug conjugates (ADCs) in preclinical studies, including overcoming ADC resistance and showing sustained CD8-positive T cell-mediated immune responses. The findings, to be presented at the AACR 2026 conference in San Diego, position ABN202 as a potential first-in-class treatment for solid tumor patients who have failed prior ADC-based therapies, with the company targeting an IND submission in the first half of next year and actively exploring strategic partnership opportunities.